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Abstract
The participation of the kallikrein-kinin system, comprising the serine
proteases kallikreins, the protein substrates kininogens and the effec-
tive peptides kinins, in some pathological processes like hypertension
and cardiovascular diseases is still a matter of controversy. The use of
different experimental set-ups in concert with the development of
potent and specific inhibitors and antagonists for the system has
highlighted its importance but the results still lack conclusivity. Over
the last few years, transgenic and gene-targeting technologies associ-
ated with molecular biology tools have provided specific information
about the elusive role of the kallikrein-kinin system in the control of
blood pressure and electrolyte homeostasis. cDNA and genomic se-
quences for kinin receptors B2 and B1 from different species were
isolated and shown to encode G-protein-coupled receptors and the
structure and pharmacology of the receptors were characterized. Trans-
genic animals expressing an overactive kallikrein-kinin system were
established to study the cardiovascular effects of these alterations and
the results of these investigations further corroborate the importance
of this system in the maintenance of normal blood pressure. Knockout
animals for B2 and B1 receptors are available and their analysis also
points to the role of these receptors in cardiovascular regulation and
inflammatory processes. In this paper the most recent and relevant
genetic animal models developed for the study of the kallikrein-kinin
system are reviewed, and the advances they brought to the understand-
ing of the biological role of this system are discussed.
Correspondence
J.B. Pesquero
Departamento de Biofísica
UNIFESP
Rua Botucatu, 862, 7º andar
04023-062 São Paulo, SP
Brasil
Fax: 55 (011) 571-5780
E-mail: jbpesq@biofis.epm.br
Presented at the II International
Symposium on Vasoactive Peptides,
Ouro Preto, MG, Brasil,
October 6-8, 1997.
Publication supported by FAPESP.
J.B. Pesquero was the recipient
of a post-doctoral fellowship from
CNPq and from the Max-Delbrück
Center for Molecular Medicine
(MDC).
Received February 4, 1998
Accepted March 17, 1998
Key words
• Kallikrein
• Kinins
• Bradykinin
• Molecular biology
• Transgenics
Introduction
The kallikrein-kinin system (KKS) is an
intricate endogenous system thought to be
involved in the regulation of blood pressure
and inflammation, amongst other processes.
This system comprises the enzymes kal-
likreins, the protein precursors kininogens
and the potent vasoactive peptides kinins.
Kallikreins are serine proteases found in
glandular cells, neutrophils and biological
fluids and are divided into two main groups:
the tissue or glandular kallikrein and the
plasma kallikrein. These are different en-
zymes encoded by distinct genes; they differ
in molecular weight, amino acid composi-
tion, types of kinins released and, more im-
portantly, function (1). The vasoactive com-
ponents of this system, the kinins, are re-
leased through the action of kallikreins on
the kininogens, and they mediate a wide
range of physiological actions related to car-
diovascular homeostasis, inflammatory and
algesic responses, as well as pain-transmit-
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ting mechanisms (1). Pharmacological stud-
ies have demonstrated that kinins promote
their biological activities through the activa-
tion of at least two different receptor sub-
types, denominated B1 and B2. Stimulation
of the B2 receptor results in intense vasodi-
lation, increased blood flow and hypoten-
sion (1). In the central nervous system, how-
ever, bradykinin (BK) promotes systemic
vasoconstriction, increased peripheral resis-
tance and hypertensive responses also via
stimulation of B2 receptors (2). Other ef-
fects mediated by B2 receptors include con-
traction of the bronchopulmonary tree, in-
creased sperm motility, release of cytokines,
prostacyclin, and nitric oxide, as well as
stimulation of cell proliferation (1). BK, kal-
lidin and the other intact kinins can exert
their biological function by binding with
high affinity to the B2 receptors whereas the
products of the action of the arginine carbox-
ypeptidase (kininase I-activity) on kinins,
the C-terminal-arginine truncated kinins, are
preferential agonists for the B1 receptor (3-
5). The B1 receptor is believed to mediate
several of the inflammatory responses to
kinins (1) and, under pathological condi-
tions, contractile effects on visceral smooth
muscle (6). The B2 receptors are constitu-
tively expressed and widely distributed
throughout mammalian tissues. In contrast,
the B1 subtype is very weakly expressed
under normal conditions but can be induced
in vivo and in vitro by endotoxin, cytokines
and growth factors, indicating that these re-
ceptors may be important in inflammation
and trauma (1). Lately, due to the recent
advances in genetic and molecular biology
techniques, the role of the KKS in several
physiological processes can be analyzed in
more detail using different transgenic ani-
mal models.
Molecular biology of the
kallikrein-kinin system
In order to generate transgenic animals
overexpressing or lacking a protein, previ-
ous knowledge about the molecular struc-
ture of the gene coding for this protein is
necessary. The molecular biology of the KKS
of many species like humans, rabbits, rats,
and mice, including the kallikreins, the
kininogens and the receptors, was clarified
over the last decade. The structure of tissue
kallikrein genes from different species and
of genes for the kininogens was described in
detail elsewhere (for review see 7-9). Re-
garding the kinin receptors, only recently
was the cDNA sequence for the rat B2 recep-
tor determined by McEachern et al. (10).
The authors used a clonal selection strategy
based on the injection of size-selected mRNA
from rat uterus into Xenopus laevis oocytes
and measurement of a BK-induced chloride
current (10). The protein predicted from the
cloned sequence belongs to the seven trans-
membrane G protein-coupled superfamily
of receptors. The knowledge of the rat B2
receptor sequence permitted the cloning of
the human and mouse B2 receptor cDNA
and genomic clones by a combined approach
of PCR using degenerate primers and library
screening (11,12). In parallel, based on the
sequence homology shared by genes encod-
ing G-protein-coupled receptors and using
low-stringency PCR and human genomic
DNA, Eggerickx et al. (13) were able to
isolate a genomic clone of the human B2
receptor. The isolation and characterization
of the genomic structure of the B2 receptor
from rats (14) and other species like humans
(15,16) and mice (17) were later achieved.
By screening a rat genomic library, we iso-
lated and analyzed the rat BK B2 receptor
gene (14). The complete genomic structure
for the rat B2 receptor gene was determined,
including exon-intron boundaries and the
promoter region (14). Differently from the
human B2 receptor gene, which encompasses
3 exons (15), the rat gene was shown to
consist of 4 exons spanning 32 kb of geno-
mic DNA. Exon 3 was shown to be alterna-
tively spliced. The exon 1 sequence of the rat
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B2 gene described by Ma et al. (18) was
shown to contain the exon 2 sequence of the
gene, and the promoter region proposed by
the authors is in fact an intron sequence.
Based on the published analysis of the mouse
B2 receptor sequence (18), it is likely that
the mouse B2 receptor also contains 4 exons,
since its coding sequence is 90% homolo-
gous to the rat homolog and exon 2 and 1
present around 80% and 70% homology to
the rat exons 3 and 2, respectively. This
question must still be addressed by other
approaches like primer extension and RNase
protection experiments. Using the technique
of primer extension analysis we identified
the promoter region of the rat B2 receptor
gene and we measured its ability to drive the
transcription of a luciferase reporter gene in
the BK B2 receptor expressing the cell line
NG108-15 (14). A cAMP-responsive ele-
ment-like sequence, which is also conserved
in the human promoter region (15), was
identified in the core promoter region and
found to be functional (19). We also have
shown that the regulatory effect produced by
the activated ras protein leading to an in-
crease in the BK B2 receptor number on the
cell surface is most likely caused by tran-
scriptional activation of the BK B2 receptor
gene since it can be mimicked only using its
promoter fused to luciferase as a reporter
gene (19). These studies will be continued
with the use of deletion mutants containing
various lengths of the B2 receptor promoter
region cloned in front of the luciferase re-
porter gene. In the rat B2 receptor gene
promoter region, like in the human promoter
(15), and most probably in the mouse se-
quence (17) there are no typical TATA or
CCAAT sequences. The genomic organiza-
tion of the B2 receptor of different species is
shown in Figure 1.
The pharmacology of the B1 receptor has
been studied for a long time (20), although
its molecular cloning was performed only
very recently.  Menke et al. (21) isolated a
human B1 receptor clone from a human
embryonic lung fibroblast cDNA library. The
authors used the method of injection of su-
crose-gradient size-fractionated mRNA from
IL-1ß-induced IMR-90 cells into Xenopus
laevis oocytes and the photoprotein aequorin
as an indicator of the ability of the B1 agonist
desArg10-kallidin to mediate Ca2+ mobiliza-
tion. The isolated sequence was also shown
to encode a protein with the characteristic
seven transmembrane domains typical of the
G-protein-coupled receptors but shared a
rather low sequence identity with the brady-
kinin B2 receptor. In the following months,
B1 receptors from other species were also
cloned and characterized (22-26). All the
different B1 receptors isolated were shown
to possess high affinity for the B1 agonists
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Kammerer et al. (15)
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Mouse
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Figure 1 - Genomic organization
of human, rat and mouse brady-
kinin B2 receptors. The mouse
gene structure is proposed
based on the sequence homol-
ogy to exons 2 and 3 of the rat
gene. The length of intron 1 (25
kb) is only known for the rat
gene (19).
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desArg10-kallidin and desArg9-BK and low
affinity for the B2 agonists. Furthermore,
they presented a high degree of amino acid
identity but displayed some prominent dif-
ferences. For instance, rat (27) and mouse
B1 (26,28) receptors have an insertion of 11
and 8 amino acids, respectively, in the first
intracellular loop when compared to the hu-
man (24,25,28) and rabbit (22) sequences.
In addition, the rodent B1 receptors are short-
ened at the C-terminus due to a translational
frameshift (26,28). Since the pharmacology
of rodent B1 receptors differs from that of
the human receptor concerning the agonists
desArg9-BK and desArg10-kallidin (28), this
difference in pharmacological profile may
be attributed to these sequence differences
in the receptors.
Transgenic and knockout models for
the kallikrein-kinin system
There are two different approaches used
to generate an alteration in the genome of an
animal: the microinjection of DNA into the
nucleus of a fertilized oocyte and targeted
modification of a gene in its chromosomal
location by homologous recombination in
embryonic stem (ES)-cells. The rationale for
these approaches is presented by Bader (29)
in his review.
Tissue kallilkrein
Several animal models overexpressing
the human tissue kallikrein gene were estab-
lished using various DNA constructs, driv-
ing the kallikrein expression to different tis-
sues. Transgenic mice carrying the human
kallikrein gene under the control of the mouse
metallothionein metal-responsive promoter
expressed the human protein in several or-
gans and, similarly to the model overex-
pressing the B2 receptor (see below), dis-
played significantly lowered blood pressure
compared to control mice (30). Transgene
expression in the mice was checked by spe-
cific radioimmunoassay and ELISA for hu-
man tissue kallikrein. The decreased blood
pressure could be restored to normal levels
following administration of aprotinin, a po-
tent kallikrein inhibitor. We also used the
same DNA construct to generate a trans-
genic rat model overexpressing the human
tissue kallilkrein (31). The expression of the
construct was subsequently established in
several tissues including the heart, kidney,
lung, and brain by a specific RNase protec-
tion assay. Human kallikrein could be de-
tected in the urine of transgenic animals by
species-specific antibodies. Cardiovascular
parameters were measured in conscious,
freely moving animals by telemetric record-
ing. The rats expressing human kallikrein
had a lower 24-h mean arterial pressure in
comparison to control rats (5-10 mmHg).
Significantly, the day/night rhythm in blood
pressure was blunted in the transgenic ani-
mals. In contrast, the circadian rhythms of
heart rate and locomotor activity were nor-
mal (31). Although these two animal models
overexpressing the human tissue kallikrein
were produced in the same manner and had
the transgene expression under the control
of the same promoter (mouse metallothio-
nein), they displayed striking differences
concerning blood pressure levels. Whereas
transgene expression resulted in a strong
reduction in blood pressure in the mouse
model, in the rat model the transgene expres-
sion produced a more moderate effect. This
discrepancy can be attributed in part to the
fact that mouse kininogen is a better sub-
strate for human kallikrein than the rat sub-
strate due to the presence of a proline residue
in P2’ in the rat molecule (32). In another
mouse model, the expression of human tis-
sue kallikrein was targeted to the liver by the
use of a mouse albumin promoter (33). The
generated animals maintained high levels of
the human enzyme in the circulation and
were chronically hypotensive, presenting
blood pressure levels about 17 mmHg lower
than those of control littermates (33). Trans-
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genic mice harboring the human tissue kal-
likrein gene under the control of its native
promoter were also generated (33). Tissue
distribution of the transgene followed the
same pattern as in human tissues but the
animals displayed normal blood pressure
values.
Another component of the KKS, the kal-
likrein-binding protein, was also used for the
production of transgenic mice (34). Trans-
genic animals expressing this protein under
the control of the mouse metallothionein
promoter were hypotensive when compared
to the control litters. This paradoxical effect
is explained by the authors by a kallikrein-
independent vasodilatory action of the kal-
likrein-binding protein.
B2 receptor
Few transgenic animal models have been
generated with alteration in the B2 receptor
gene. In order to obtain more information on
the physiological function of bradykinin,
Wang et al. (35) generated a mouse model
harboring the human bradykinin B2 receptor
under the control of the Rous sarcoma virus
3’-LTR promoter. The animals expressed
the human gene in different tissues and pre-
sented a significant reduction of blood pres-
sure compared to control littermates. Al-
though the transgene expression was not
quantified or normalized with any other en-
dogenous gene, for instance the endogenous
B2 receptor, the amount of human gene ex-
pression was sufficient to produce a signifi-
cant hypotensive effect (35). The blood pres-
sure effect was caused by the presence of the
transgene since it was dependent on the gene
dose and could be blunted by the administra-
tion of the B2 receptor antagonist HOE-140.
Moreover, intra-arterial bolus injection of
bradykinin produced more pronounced va-
sodepressor effects on the blood pressure of
transgenic animals. Another approach used
to study the physiological role of the B2
receptor was the genetic ablation of this gene
by homologous recombination in stem cells.
The bradykinin B2 receptor knockout model
was generated in 1994 by Borkowski et al.
(36). The absence of B2 receptor in this
animal did not render it infertile and did not
produce any changes in morphology or litter
size, ruling out an essential role for this
receptor in reproduction and ontogenesis
(36). However, the lack of response to brady-
kinin in the uterine contraction assay and in
studies of depolarization of the superior cer-
vical ganglia performed in this model was
instrumental to demonstrate the existence of
only one B2 receptor gene. The possibility
still remains that multiple B2 receptor sub-
types could be produced in different tissues
by alternative splicing of the gene, at least in
rats (14), leading to the generation of pro-
teins with a distinct N-terminus, as demon-
strated by differential utilization of AUG
codons present in exons 3 and 4 (37) of the
rat B2 gene. Although no reference to alter-
ations in blood pressure was made in the
original paper describing the B2 receptor
knockout model (36), some authors have
reported an increase in blood pressure in
these animals (38). Furthermore, evidence
has been presented suggesting a role of ki-
nins in preventing salt-sensitive hyperten-
sion, whereby the B2 knockout mice dis-
played a greater hypertensive response to
chronic sodium intake compared to control
animals (39).
B1 receptor
So far, due to the very recent cloning of
the genes coding for the B1 receptor, only
the knockout model has been described. To
study the physiologic role of the B1 receptor
in physiopathologic states like inflammation
and also in cardiac diseases, we generated a
mouse model lacking the B1 receptor gene
(40). To generate the knockout mice, the
isolated murine B1-receptor gene (26) was
mutated in vitro by replacing the coding
region with the neomycin resistance gene.
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This construct was transfected into ES-cells,
which were subsequently screened for neo-
mycin and ganciclovir resistance. The resist-
ant clones were checked by PCR for ho-
mologous recombinants, i.e., cells contain-
ing the mutated bradykinin-B1 allele at the
correct chromosomal position. Homozygous
animals were shown to be viable and to
present normal development. Gene ablation
was confirmed by PCR and Southern blot
assays, checked at the RNA level by RNase
protection assays and functionally determined
by the lack of activity of B1 agonists in
stomach, ileum, and uterus muscle contrac-
tion assays. Mean arterial pressure was meas-
ured in awake mice and found not to differ
from the control littermates, ruling out the
participation of the B1 receptor in the con-
trol of blood pressure under normal condi-
tions (40).
Conclusions
The use of genetically engineered ani-
mals is an invaluable tool for unraveling the
pathogenesis of complex cardiovascular dis-
eases and many aspects of mammalian biol-
ogy. Although the molecular characteriza-
tion of the kallikrein-kinin system was started
relatively recently, many transgenic animal
models with alterations in the system have
been generated. The results presented here
and the data which will still be generated
with these and other models will be instru-
mental in elucidating the role of the proteins
of the kallikrein-kinin system for the control
of cardiovascular homeostasis and of in-
flammatory processes, both important fac-
tors in the etiology of the most common
human diseases.
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